![Paolo Tarantino: The CAPItello290 trial did not meet the dual primary endpoints](https://oncodaily.com/pub/uploads/2024/06/Pi7_Tool_24ed5e652acd43bd942359bbc985479d.png)
Paolo Tarantino: The CAPItello290 trial did not meet the dual primary endpoints
Paolo Tarantino shared on X/Twitter:
“Press Release: the CAPItello290 trial of 1L paclitaxel +/- capivasertib in advanced TNBC did not meet the dual primary endpoints of OS in the overall population or in patients with AKT-pathway-mutant disease.”
Read further.
Source: Paolo Tarantino/X
Dr. Paolo Tarantino, MD researcher, holds positions at both the European Institute of Oncology in Milan, Italy, and the Dana-Farber Cancer Institute in Boston, MA, Specializing in breast cancer. Currently, Dr. Tarantino is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.
His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a robust publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field. Dr. Tarantino’s dedication and innovative approach contribute significantly to the advancement of breast cancer treatment and research.